|
gptkbp:instanceOf
|
immunotherapy
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvedBy
|
gptkb:non-small_cell_lung_cancer
gptkb:urothelial_carcinoma
gptkb:triple-negative_breast_cancer
2016
hepatocellular carcinoma
renal cell carcinoma
|
|
gptkbp:canBe
|
combination drug
monotherapy
|
|
gptkbp:cause
|
hepatitis
inflammatory bowel disease
pneumonitis
endocrinopathies
|
|
gptkbp:combines
|
chemotherapy
targeted therapy
other immunotherapies
|
|
gptkbp:contraindication
|
severe autoimmune disease
|
|
gptkbp:developedBy
|
gptkb:Pfizer
gptkb:AstraZeneca
gptkb:Roche
|
|
gptkbp:enhance
|
T-cell immune response
|
|
gptkbp:example
|
gptkb:durvalumab
gptkb:atezolizumab
gptkb:avelumab
|
|
gptkbp:hasBiomarker
|
gptkb:PD-L1_expression
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PD-L1 inhibitors
|
|
gptkbp:inducedBy
|
immune-related toxicity
long-term remission
|
|
gptkbp:mechanismOfAction
|
block interaction between PD-L1 and PD-1
prevent tumor immune evasion
|
|
gptkbp:monitors
|
clinical assessment
imaging
blood tests
|
|
gptkbp:notEffectiveAgainst
|
all cancer types
|
|
gptkbp:notRecommendedFor
|
organ transplant recipients
|
|
gptkbp:regulates
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:relatedTo
|
gptkb:PD-1_inhibitors
|
|
gptkbp:researchArea
|
immunology
oncology
|
|
gptkbp:sideEffect
|
diarrhea
fatigue
rash
immune-related adverse events
|
|
gptkbp:target
|
PD-L1 protein
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:PD-L1_expression
|
|
gptkbp:bfsLayer
|
6
|